Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

Saturday, May 31, 2008 General News J E 4
SAN CARLOS, Calif., May 30 Nektar Therapeutics(Nasdaq: NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102(PEG-irinotecan). The Webcast will include a presentation by featured speakerDr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator atthe Translational Genomics Research Institute (TGen), Chief Scientific Officerfor the Scottsdale Clinical Research Institute at Scottsdale Healthcare, andChief Scientific Officer of US Oncology.

A live audio-only Webcast of this presentation can be accessed beginningat 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektarwebsite: A replay will also be accessiblethrough the same link through June 15, 2008.

To attend this event in person, please RSVP no later than Sunday, June 1,2008 to Vanessa Rivas:

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar PEGylation technology hasenabled eight approved products for partners, which include leadingpharmaceutical and biotechnology companies. Nektar also develops its ownproducts by applying its PEGylation and pulmonary technology platforms toexisting medicines with the objective to enhance performance, such asimproving efficacy, safety and compliance.

Contact: Jennifer Ruddock, +1-650-283-6253, jruddock@nektar.comTime: 6:00 - 6:30 PM (Central Time) -- Registration 6:30 PM (Central Time) -- Webcast presentation Location: Fulton's on the River Riverfront Room and Veranda 315 N. LaSalle Street Chicago, IL 60610

SOURCE Nektar Therapeutics


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Technological Interventions Merge Into Health and ...
Lifetime Medical Organizer